Overall rank by patents
#26,123
of 50,000 tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, recorded in grant years 2017–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).
The verdict
According to USPTO PatentsView, Diasorin ranks #26,123 of 50,000 tracked US assignees by granted-patent volume, with 10 patents across 6 technology areas.
USPTO PatentsView assignee plate
Corpus R26123 · Foreign Corporation #26,123 · 10 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Deutsches Rheuma-forschungszentrum Berlin (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Diasorin S p a · this assignee
29 score
3D Lighting Innovati… · lowest
7 score
What this shows Diasorin's Innovation Score is 29.4/100 (top 70% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Diasorin S.p.a. is a focused PatentsView assignee: 6 CPC subclasses with 60% of grants classified under C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2017. By volume, Diasorin sits between Deutsches Rheuma-forschungszentrum Berlin and Dna2.0, Inc..
Diasorin S.p.a. shows 2 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN
10 patents
DEVAR ENTERTAINMENT LIMITED
10 patents
DEVON ENERGY CORPORATION
10 patents
DIAGNOSTICA STAGO
10 patents
DIGITAL CHECK CORP.
10 patents
DIGIWIN CO., LTD.
10 patents
DISCOURSE.AI, INC.
10 patents
DNA2.0, INC.
10 patents
DIASORIN S.p.A.
10 patents
What this shows Diasorin holds 10 patents at rank #26,103, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #26,103 in granted patent volume.
Other assignees with the most granted patents in Diasorin's primary technology class.
Diasorin's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
29 Top 70% higher than 30% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 10.0% |
| 2018 | 1 | 10.0% |
| 2019 | 2 | 20.0% |
| 2020 | 1 | 10.0% |
| 2021 | 3 | 30.0% |
| 2022 | 1 | 10.0% |
| 2023 | 1 | 10.0% |
Top 6 of 6 technology areas
Overall rank by patents
#26,123
of 50,000 tracked assignees
29.4 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.